1
|
Chen KW, Chung KP, Hsu CH. The intention of utilization and experience toward traditional Chinese medicine among breast cancer patients in the early and late stages: a qualitative study. BMC Complement Med Ther 2023; 23:226. [PMID: 37420247 DOI: 10.1186/s12906-023-04054-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Accepted: 06/24/2023] [Indexed: 07/09/2023] Open
Abstract
BACKGROUND In Taiwan, breast cancer patients usually take conventional medicine and traditional Chinese medicine simultaneously. The utilization of traditional Chinese medicine among breast cancer patients at various stages has not been examined. This study aims to compare the intention of utilization and experience toward traditional Chinese medicine among early- and late-stage breast cancer patients. METHOD This qualitative research collected data from breast cancer patients through focus groups interview by convenience sampling. Conducted in 2 branches of Taipei City Hospital, a public hospital managed by the Taipei City government. Breast cancer patients > 20 years old and had used TCM for breast cancer therapy for at least 3 months were included in the interview. A semi-structured interview guide was adopted in each focus group interview. In the following data analysis, stages I and II were considered early-stage, and stages III and IV were late-stage. For analyzing the data and reporting the results, we used qualitative content analysis as the approach for data analysis, assisted by NVivo 12. Categories and subcategories were identified through content analysis. RESULTS Twelve and seven early- and late-stage breast cancer patients were included in this study, respectively. The side effects were the main intention of utilizing traditional Chinese medicine. Improving side effects and constitution was the main benefit for patients in both stages. Additionally, early-stage breast cancer patients used traditional Chinese medicine to prevent recurrence or metastasis. Late-stage breast cancer patients responded more frequently to the use of traditional Chinese medicine due to the side effects of western medicine. However, some of their symptoms were not fully relieved. CONCLUSIONS Breast cancer staging may influence the intention and utilization of traditional Chinese medicine. Health policymakers should consider the results of this research and the evidence-based illustrations to establish guidelines for integrating traditional Chinese medicine among various stages of breast cancer to improve the outcome and quality of care for cancer patients.
Collapse
Affiliation(s)
- Kai-Wei Chen
- Institute of Health Policy and Management, National Taiwan University, 17 Xuzhou Road, Zhongzheng District, Taipei City, 100, Taiwan
- Linsen, Chinese Medicine and Kunming Branch, Taipei City Hospital, 100 Kunming Street, Wanhua District, Taipei City, 108, Taiwan
| | - Kuo-Piao Chung
- Institute of Health Policy and Management, National Taiwan University, 17 Xuzhou Road, Zhongzheng District, Taipei City, 100, Taiwan.
| | - Chung-Hua Hsu
- Linsen, Chinese Medicine and Kunming Branch, Taipei City Hospital, 100 Kunming Street, Wanhua District, Taipei City, 108, Taiwan
| |
Collapse
|
2
|
Zhao Q, Guo R, Fan Z, Hu L, Hu Z, Liu Y. Medical Conditions and Preference of Traditional Chinese Medicine: Results from the China Healthcare Improvement Evaluation Survey. Patient Prefer Adherence 2023; 17:227-237. [PMID: 36718438 PMCID: PMC9883991 DOI: 10.2147/ppa.s398644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 01/14/2023] [Indexed: 01/25/2023] Open
Abstract
PURPOSE Although complementary and alternative medicine (CAM) is used around the world, there has been a lack of comprehensive understanding of major factors affecting patients' decision to use CAM. This study aimed to describe the preferences of Chinese patients regarding what conditions they will use Traditional Chinese Medicine (TCM) for and to determine the factors associated with these preferences. PATIENTS AND METHODS This study used data from the China Healthcare Improvement Evaluation Survey in January 2021, a national cross-sectional survey conducted at 163 hospitals across 31 provinces. A convenient sampling method was used to conduct the patient satisfaction survey, and 28,993 patients in an ambulatory setting constituted our study sample on TCM use. A multiple-choice question regarding TCM listed nine medical conditions and asked the patient about what condition he/she and his/her family members would use TCM. In addition to descriptive statistics, we used a binary logistic regression model to investigate factors affecting the likelihood of patients' decision to use TCM for multiple conditions. RESULTS The majority of the surveyed patients (76.3%) would use TCM for the purpose of disease prevention, and more than half (67.3%) for multiple medical/health conditions, 34.0% for dealing with chronic diseases, 33.0% for common symptoms, 26.9% for rehabilitation, and 26.3% for sleeping disorder. Female and older patients, as well as patients with a higher education level, urban residency, and higher family income, were found to be associated with a higher probability of using TCM for multiple conditions than their counterparts (odd ratios [OR]>1, P<0.05). CONCLUSION This study reveals a preference for TCM in a large sample of Chinese patients, especially used for prevention. Generally, patients with a higher socioeconomic status had a more positive attitude toward TCM.
Collapse
Affiliation(s)
- Qi Zhao
- School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People’s Republic of China
| | - Ran Guo
- School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People’s Republic of China
| | - Zixuan Fan
- School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People’s Republic of China
| | - Linlin Hu
- School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People’s Republic of China
| | - Zhimin Hu
- School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People’s Republic of China
| | - Yuanli Liu
- School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, People’s Republic of China
- Correspondence: Yuanli Liu, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 9 Dongdansantiao, Dongcheng District, Beijing, 100730, People’s Republic of China, Email
| |
Collapse
|
3
|
Qi XY, Liu H, Bi DD, Wang XT, Guo YF, Hao T, Zhang BX, Wang XG, Han MH. Combined administration on You-Gui Yin and low-dose Raloxifene partially attenuates the bone loss in ovariectomized mice through the proliferation and osteogenic differentiation of bone marrow stromal cells. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2019; 53:286-293. [PMID: 30668409 DOI: 10.1016/j.phymed.2018.09.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Revised: 07/16/2018] [Accepted: 09/03/2018] [Indexed: 06/09/2023]
Abstract
BACKGROUND Osteoporosis is a systemic skeletal disease of fragility fractures due to the loss of mass and deterioration of the microarchitecture of bone. PURPOSE The aim of the study was to assess the osteogenic effects and the underlying mechanisms of the combined administration of You-Gui Yin (YGY) and Raloxifene hydrochloride (RLX) in ovariectomized (OVX) mice. METHODS First, a classic animal model was used to mimic postmenopausal osteoporosis through the removal of the ovary of mice. Second, the OVX mice were administered YGY, RLX, and YGY + RLX for 12 weeks. Next, the bone microtomographic histomorphometry and bone mineral density (BMD) were assessed by micro-CT, and the biochemical markers of procollagen type I N-terminal propeptide (P1NP) and beta-isomerized C-telopeptide (β-CTX) in serum were assessed. Finally, primary bone marrow stromal cells (BMSCs) were isolated from the tibia and cultured to evaluate cell proliferation and osteogenic differentiation. RESULTS The results showed that BMD on the YGY + RLX group was higher than that on the RLX group (p < 0.05) and did not have a significant difference when compared with the sham group. Notably, the YGY + RLX group had a dramatically increased trabecular number (Tb.N) compared with that of the YGY group (p < 0.05). Moreover, the BV/TV (bone volume/total volume) and Tb.N in the YGY + RLX group were higher than that in the RLX group (p < 0.05), and the Tb.Sp (trabecular separation) was lower than that in the RLX group (p < 0.05). Moreover, the serum level of P1NP from the YGY + RLX group dramatically increased when compared with that from the YGY and RLX groups (YGY group: p < 0.05; RLX groups: p < 0.01). Notably, there was no significant difference between the YGY and YGY + RLX groups. In addition, cell proliferation from the co-administration of YGY and RLX was clearly higher than a single use of YGY and RLX (p < 0.01, respectively). The ALP/BCA (alkaline phosphatase/bicinchoninic acid) in the YGY + RLX group was higher than that in the RLX group (p < 0.01). CONCLUSION Overall, co-administered YGY and RLX could partially attenuate bone loss and were more effective than individually using either one; this outcome might be associated with the proliferation and osteogenic differentiation of BMSCs.
Collapse
Affiliation(s)
- Xiao-Yu Qi
- Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Room 109, Chemistry Building, 151 Malianwa North Road, Haidian District, Beijing 100193, China; College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China
| | - Hao Liu
- The Core Laboratory, Peking University School and Hospital of Stomatology, Beijing 100081, China
| | - Dong-Dong Bi
- Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Room 109, Chemistry Building, 151 Malianwa North Road, Haidian District, Beijing 100193, China
| | - Xiang-Tao Wang
- Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Room 109, Chemistry Building, 151 Malianwa North Road, Haidian District, Beijing 100193, China
| | - Yi-Fei Guo
- Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Room 109, Chemistry Building, 151 Malianwa North Road, Haidian District, Beijing 100193, China
| | - Ting Hao
- Department of Trauma, the Second Affiliated Hospital of Inner Mongolia Medical University, 1 Cultural Palace Street, Huimin District, Hohhot 010030, China
| | - Bao-Xin Zhang
- Department of Trauma, the Second Affiliated Hospital of Inner Mongolia Medical University, 1 Cultural Palace Street, Huimin District, Hohhot 010030, China
| | - Xing-Guo Wang
- Department of Trauma, the Second Affiliated Hospital of Inner Mongolia Medical University, 1 Cultural Palace Street, Huimin District, Hohhot 010030, China.
| | - Mei-Hua Han
- Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Room 109, Chemistry Building, 151 Malianwa North Road, Haidian District, Beijing 100193, China.
| |
Collapse
|
4
|
Sun L, Mao JJ, Vertosick E, Seluzicki C, Yang Y. Evaluating Cancer Patients' Expectations and Barriers Toward Traditional Chinese Medicine Utilization in China: A Patient-Support Group-Based Cross-Sectional Survey. Integr Cancer Ther 2018; 17:885-893. [PMID: 29888609 PMCID: PMC6142069 DOI: 10.1177/1534735418777117] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Background: Traditional Chinese medicine (TCM) is widely used among
Chinese cancer patients. However, little is known about Chinese patients’
expectations and barriers toward using TCM for cancer. Methods: We
conducted a cross-sectional survey within a patient-support group, the Beijing
Anti-Cancer Association. We measured the outcome, Chinese cancer survivors’
expectations and barriers toward TCM utilization, using a modified version of
ABCAM (Attitudes and Beliefs towards Complementary and Alternative Medicine),
the ABTCM (Attitudes and Beliefs towards Traditional Chinese Medicine). We used
multivariate models to evaluate the impact of socioeconomic status and clinical
factors on their expectations and barriers (including treatment concerns and
logistical challenges domain) toward TCM. Results: Among 590
participants, most patients expected TCM to boost their immune system (96%),
improve their physical health (96%), and reduce symptoms (94%). Many had
logistical challenges (difficulty decocting herbs (58%) and finding a good TCM
physician (55%)). A few were concerned that TCM might interfere with
conventional treatments (7.6%), and that many TCM treatments are not based on
scientific research (9.1%). In the multivariable regression model, age ≤60 years
was independently associated with higher expectation score (P =
.031). Age ≤60 years (coefficient 5.0, P = .003) and localized
disease (coefficient 9.5, P = .001) were both associated with
higher treatment concerns. Active employment status (coefficient 9.0,
P = .008) and localized disease (coefficient 7.5,
P = .030) were related to more logistical challenges.
Conclusion: Age and cancer stage were related to Chinese cancer
patients’ perceived expectations and barriers toward TCM use. Understanding
these attitudes is important for reshaping the role that TCM plays in China’s
patient-centered comprehensive cancer care model.
Collapse
Affiliation(s)
- Lingyun Sun
- 1 Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.,2 Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Jun J Mao
- 2 Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | | - Yufei Yang
- 1 Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|
5
|
Sun L, Yang Y, Vertosick E, Jo S, Sun G, Mao JJ. Do Perceived Needs Affect Willingness to Use Traditional Chinese Medicine for Survivorship Care Among Chinese Cancer Survivors? A Cross-Sectional Survey. J Glob Oncol 2017; 3:692-700. [PMID: 29244994 PMCID: PMC5735974 DOI: 10.1200/jgo.2016.007955] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Purpose We aimed to quantify Chinese cancer survivors' perceived needs for survivorship care and to evaluate whether these needs could impact their willingness to use traditional Chinese medicine (TCM). Methods We conducted a cross-sectional survey with members of the Beijing Anti-Cancer Association in China. We measured perceived needs with the seven-item Brief Chinese Cancer Survivorship Needs Scale that assesses psychological, functional, nutritional, social, body image, pain, and symptom needs. The outcome variable was willingness to use TCM for survivorship care. We performed multivariable logistic regression analyses to evaluate whether perceived needs are associated with willingness. Results A total of 600 patients were invited, with a response rate of 81%. The mean (standard deviation) score of the perceived needs scale (0 to 10) was 4.4 (2.2), with the majority of participants endorsing nutritional (72%), symptom (65%), and psychological (54%) needs. Among survivors, 387 (80%; 95% CI, 76% to 83%) were willing to use TCM for survivorship care. In multivariable analysis, a higher perceived needs score (adjusted odds ratio [OR], 1.33; 95% CI, 1.14 to 1.56; P < .001) was associated with greater willingness to use TCM. Specifically, nutritional (OR, 3.17; 95% CI, 1.79 to 5.62; P < .001) and symptom needs (OR, 3.15; 95% CI, 1.79 to 5.55; P < .001) had the strongest relationship. Conclusion A higher level of perceived needs, especially in the areas of nutrition and symptoms, was associated with greater willingness to use TCM for survivorship care.
Collapse
Affiliation(s)
- Lingyun Sun
- Lingyun Sun, Emily Vertosick, and Jun J. Mao, Memorial Sloan Kettering Cancer Center, New York, NY; Lingyun Sun, Yufei Yang, and SungHwa Jo, China Academy of Chinese Medical Science, and Guilan Sun, Beijing Anti-Cancer Association, Beijing, China
| | - Yufei Yang
- Lingyun Sun, Emily Vertosick, and Jun J. Mao, Memorial Sloan Kettering Cancer Center, New York, NY; Lingyun Sun, Yufei Yang, and SungHwa Jo, China Academy of Chinese Medical Science, and Guilan Sun, Beijing Anti-Cancer Association, Beijing, China
| | - Emily Vertosick
- Lingyun Sun, Emily Vertosick, and Jun J. Mao, Memorial Sloan Kettering Cancer Center, New York, NY; Lingyun Sun, Yufei Yang, and SungHwa Jo, China Academy of Chinese Medical Science, and Guilan Sun, Beijing Anti-Cancer Association, Beijing, China
| | - SungHwa Jo
- Lingyun Sun, Emily Vertosick, and Jun J. Mao, Memorial Sloan Kettering Cancer Center, New York, NY; Lingyun Sun, Yufei Yang, and SungHwa Jo, China Academy of Chinese Medical Science, and Guilan Sun, Beijing Anti-Cancer Association, Beijing, China
| | - Guilan Sun
- Lingyun Sun, Emily Vertosick, and Jun J. Mao, Memorial Sloan Kettering Cancer Center, New York, NY; Lingyun Sun, Yufei Yang, and SungHwa Jo, China Academy of Chinese Medical Science, and Guilan Sun, Beijing Anti-Cancer Association, Beijing, China
| | - Jun J. Mao
- Lingyun Sun, Emily Vertosick, and Jun J. Mao, Memorial Sloan Kettering Cancer Center, New York, NY; Lingyun Sun, Yufei Yang, and SungHwa Jo, China Academy of Chinese Medical Science, and Guilan Sun, Beijing Anti-Cancer Association, Beijing, China
| |
Collapse
|
6
|
Jiang Tang Xiao Ke Granule, a Classic Chinese Herbal Formula, Improves the Effect of Metformin on Lipid and Glucose Metabolism in Diabetic Mice. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2016; 2016:1592731. [PMID: 27418937 PMCID: PMC4932160 DOI: 10.1155/2016/1592731] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Revised: 04/30/2016] [Accepted: 05/24/2016] [Indexed: 12/19/2022]
Abstract
In the present study, the hypoglycemic, hypolipidemic, and antioxidative effects of metformin (MET) combined with Jiang Tang Xiao Ke (JTXK) granule derived from the “Di Huang Tang” were evaluated in mice with type 2 diabetes mellitus (DM) induced by high-fat diet/streptozotocin. DM mice were orally treated with MET (0.19 g/kg) either alone or combined with different doses (1.75, 3.5, or 7 g/kg) of JTXK for 4 weeks. Results showed that the serum and hepatic glucose, lipids, and oxidative stress levels were elevated in DM mice, when compared with the normal mice. MET treatment decreased FBG and serum glucagon levels of DM mice. Combination treatment with MET and JTXK 3.5 g/kg increased the hypoglycemia and insulin sensitivity at 4 weeks when compared with the DM mice treated with MET alone. However, neither MET nor MET/JTXK treatment could completely reverse the hyperglycemia in DM mice. JTXK enhanced the serum triglyceride (TG) and hepatic lipid-lowering effect of MET in a dose-dependent manner in DM mice. JTXK 1.75 and 3.5 g/kg improved the hepatoprotective effect of MET in DM mice. Synergistic effect of combination treatment with MET and JTXK on antioxidant stress was also found in DM mice compared with MET alone.
Collapse
|